PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that once every-2-weeks and once every-4-weeks
treatment with epoetin alfa, a drug that increases red blood cell production, in patients
with anemia associated with chronic kidney disease, is not less effective than treatment with
epoetin alfa that is given once a week
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.